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Abstract
Background—The association between serum sex steroid hormones and PSA in a general 
population has not been described.
Methods—Included were 378 men aged 40-85 years who participated in the National Health and 
Nutrition Examination Survey in 2001-2004, who did not have a prostate cancer diagnosis, and 
had not had a recent biopsy, rectal examination, cystoscopy, or prostate infection or inflammation. 
Serum total PSA, total testosterone, androstanediol glucuronide (3α-diol-G), estradiol, and sex 
hormone binding globulin (SHBG) concentrations were previously measured. Free testosterone 
was estimated by mass action. We applied sampling weights and calculated geometric mean PSA 
concentration by hormone quintiles adjusting for age and race/ethnicity, and also for body mass 
index, waist circumference, smoking, diabetes, and mutually for hormones. We estimated the OR 
of PSA ≥2.5 ng/mL per hormone quintile using logistic regression.
Results—Geometric mean PSA increased across testosterone quintiles after age and race/
ethnicity (Q1: 0.80, Q5: 1.14 ng/mL; P-trend=0.002) and multivariable (Q1: 0.79, Q5: 1.16 
ng/mL; P-trend=0.02) adjustment; patterns were similar for free testosterone and 3α-diol-G. 
SHBG was inversely associated with PSA only after multivariable adjustment (Q1: 1.32, Q5: 0.82 
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nmol/L; P-trend=0.01). Estradiol and PSA were not associated. The OR of PSA ≥2.5 ng/mL was 
1.54 (95% CI 1.18-2.01) per testosterone quintile after age and race/ethnicity adjustment, and 1.78 
(95% CI 1.16-2.73) after multivariable adjustment.
Conclusions—In this nationally representative sample, men with higher testosterone had higher 
PSA even after taking into account other hormones and modifiable factors. Men with higher 
SHBG had lower PSA, but only after multivariable adjustment.
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Introduction
Prostate specific antigen (PSA)-based prostate cancer screening is controversial, in part, 
because of imperfect specificity, especially for aggressive disease [1]. PSA production by 
prostate luminal epithelial cells is under androgenic regulation [2]. However, the association 
between circulating androgen and PSA levels is unclear in general populations of men. 
Thus, we investigated the association between serum concentrations of total PSA and 
androgens – total testosterone, free testosterone, and androstanediol glucuronide (3α-diol-G) 
– in men without a prostate cancer diagnosis in the continuous National Health and Nutrition 
Examination Survey (NHANES), a nationally representative sample of non-institutionalized 
Americans. We also investigated the association of estradiol and sex hormone binding 
globulin (SHBG), which carries both testosterone and estradiol in circulation, with PSA in 
these men. We hypothesized that men with higher circulating concentrations of total 
testosterone, free testosterone, and 3α-diol-G, and lower concentrations of SHBG and 
estradiol would have a higher PSA. Knowledge of this association may be used in the future 
to enhance clinical decision-making for an elevated screening serum PSA.
Materials and Methods
Study population
NHANES is a series of cross-sectional studies conducted by the National Center for Health 
Statistics of the Centers for Disease Control and Prevention [3]. By design, each cycle of 
NHANES is representative of the total civilian non-institutionalized population of adults and 
children aged two months or older in the United States. It utilizes a multistate stratified 
probability sample and includes an oversampling of Hispanics, non-Hispanic blacks and the 
elderly to allow for more precise estimates in these subgroups. This analysis included men 
from two cycles of continuous NHANES, 2001-2002 and 2003-2004. Unbiased national 
estimates of health and nutritional characteristics can be independently produced for each 
cycle.
As part of NHANES 2001-2002 and 2003-2004, serum total PSA concentration was 
measured in men who were at least 40 years of age, who consented, and who did not have a 
past prostate cancer diagnosis, recent biopsy, rectal examination, or cystoscopy, or current 
infection or inflammation of the prostate. Serum for sex steroid hormone concentrations was 
measured in a sub-sample of men at least 20 years of age and who participated in the 
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morning examination session in NHANES 1999-2004 [4]. The overlap between the 
measurement of PSA and hormone concentrations was 410 men who were aged 40-85 years. 
We excluded 23 men with missing baseline characteristics (height, weight, waist 
circumference, smoking status, diabetes) and 9 men who had missing values for at least one 
of the sex steroid hormones that were measured. Thus, 378 men were included in the 
analysis.
Measurement of sex steroid hormone, SHBG, and PSA concentrations
Sex steroid hormone concentrations were measured in the laboratory of Dr. Nader Rifai 
(Children's Hospital, Boston, MA). Total testosterone, total estradiol, and SHBG 
concentrations were assayed using electrochemiluminescence immunoassays on the Elecsys 
2010 autoanalyzer (Roche Diagnostics, Indianapolis, IN). Concentration of 3α-diol-G, a 
metabolite of dihydrotestosterone, was assayed using the direct 3α-Diol-G ELISA kit 
(ALPCO Diagnostics, Salem, NH); in this analysis we use 3α-diol-G as a surrogate for 
dihydrotestosterone. The assay limits of detection were: total testosterone (0.02 ng/mL), 3α-
diol-G (0.33 ng/mL), total estradiol (5 pg/mL), and SHBG (3 nmol/L). Coefficients of 
variation for 21 samples assayed in duplicate were: 4.8% for total testosterone, 9.7% for 3α-
diol-G, 21.4% for total estradiol, and 5.6% for SHBG. All men had measured total 
testosterone, 3α-diol-G, and SHBG concentrations above their respective limits of detection. 
Four men had a measured estradiol concentration below the limit of detection; concentration 
was imputed by modeling the distribution of estradiol concentrations above 5 pg/mL, 
extrapolating this distribution below the limit of detection, and randomly sampling values 
between 0 and 5 pg/mL from the extrapolated probability distribution. Free testosterone was 
calculated from the total testosterone, SHBG and serum albumin (measured using the 
Bromcresol Purple method) concentrations [5].
Serum total PSA concentration was measured using the Beckman Access Immunoassay 
System with the Hybritech Total PSA Assay (Beckman Coulter, Fullerton, CA) [6].
Measurement of covariates
Age, race/ethnicity, cigarette smoking and history of a diagnosis of type II diabetes mellitus 
were assessed by standardized in-home interview. Body height, body weight, waist 
circumference and fasting glucose were measured during a mobile medical examination 
center visit. Race/ethnicity was categorized as non-Hispanic white, non-Hispanic black, 
Hispanic (combined Mexican-American and other Hispanic), and Other. Cigarette smoking 
was categorized as never (men who smoked fewer than 100 cigarettes during their lifetime), 
former (men who smoked at least 100 cigarettes in their lifetime and reported that they now 
smoke ‘not at all’), and current smokers (men who smoked at least 100 cigarettes in their 
lifetime and reported they now smoke ‘every day’ or ‘some days’). We categorized men as 
non-diabetic (no diagnosis of diabetes from a doctor and fasting glucose <100 mg/dL), pre-
diabetic (no diagnosis of diabetes from a doctor and fasting glucose between 100 and 125 
mg/dL), and diabetic (diagnosis of diabetes from a doctor or fasting glucose >125 mg/dL). 
Body mass index (BMI, kg/m2) was calculated from weight and height.
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Statistical analysis
In all analyses we used the morning sampling weights to account for the NHANES complex 
survey design. We calculated demographic characteristics of the men, including age and 
race/ethnicity, and age- and race/ethnicity-adjusted BMI, waist circumference, cigarette 
smoking status and diabetes across quintiles of total testosterone concentration. We 
estimated P-values for differences among quintiles from Wald chi-square tests for 
proportions and one-way ANOVAs for means. Additionally, we determined P-trends for 
mean age, BMI and waist circumference from a Wald F-test modeling total testosterone as a 
single ordinal variable based on quintile.
Because serum PSA concentration was not normally distributed, it was transformed using 
the natural logarithm. Then, we estimated geometric mean serum PSA concentration and 
95% confidence interval by weighted quintile of concentrations of total testosterone, free 
testosterone, 3α-diol-G, estradiol, and SHBG. We evaluated the trend in geometric mean 
PSA concentration across hormone quintiles by modeling each hormone concentration as a 
single ordinal variable, assigning each man the median concentration within his quintile, and 
evaluating its statistical significance using the Student's T-test.
Age- and race/ethnicity- adjusted and multivariable-adjusted geometric means were 
estimated using predicted margins from linear regression models. Age in years, 
parameterized as a restricted quadratic spline with three knots at the 10th, 50th and 90th 
percentiles, and race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Other) 
were included in all models. Multivariable models were further adjusted for BMI (normal 
[<25 kg/m2], overweight [25-29.9 kg/m2], obese [≥30.0 kg/m2]), waist circumference (<94 
cm, 94 to <102 cm, ≥102 cm), cigarette smoking status (non-smoker, former smoker, current 
smoker), diabetes (non-diabetic, pre-diabetic, diabetic), and mutually for the other hormones 
as natural logarithm-transformed continuous variables (total testosterone: estradiol and 
SHBG; free testosterone: estradiol; 3α-diol-G: estradiol and SHBG; estradiol: total 
testosterone and SHBG; SHBG: total testosterone and estradiol).
We estimated multivariable-adjusted geometric mean serum PSA concentration by quintile 
of hormone concentration stratified by categories of race/ethnicity, adiposity (high: BMI 
above the median of 28 kg/m2 or waist ≥102 cm; low: BMI at or below the median of 28 
kg/m2 and waist circumference <102 cm [7]), and age (younger: at or above the median of 
52 years, older: >52 years). Stratum-specific estimates were generated using a common 
model, allowing for the comparison across strata (e.g., geometric means for PSA by total 
testosterone quintiles can be compared across non-Hispanic whites, non-Hispanic blacks, 
and Hispanics, etc.). We tested for interactions by including the main effects terms for the 
hormone and the stratification factor, along with a term for their product, the coefficient for 
which was evaluated by conducting a Wald test.
Serum PSA concentration was categorized into higher and lower concentrations with 
cutpoints at 4.0, 2.5, and 2.0 ng/mL; these cutpoints were selected because 4.0 ng/mL is the 
most commonly used cutpoint for biopsy recommendation and these cutpoints yield 
different prostate cancer detection rates [8]. Multivariable logistic regression was used to 
estimate the odds ratios (ORs) and 95% confidence intervals (CIs) of higher serum PSA 
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concentration across quintiles of total testosterone concentration. We evaluated the trend in 
elevated serum PSA across hormone quintiles by modeling total testosterone concentration 
as a single ordinal variable, assigning each man the median concentration within his quintile, 
and evaluating its statistical significance using the Student's t-test. Statistical analyses were 
performed using Stata 12 (College Station, TX), SAS 9.3 (Cary, NC) and SUDAAN 10 
(Research Triangle Park, NC).
Results
Characteristics of the men
Characteristics of the 378 men are presented in Table I, both overall and by quintile of total 
testosterone concentration. The men had a mean age of 54.8 years and 79.0% were white. 
Mean BMI was 28.6 kg/m2 and mean waist circumference was 103.0 cm. Most men were 
overweight or obese (75.9%), 62.2% were current or former smokers, and 51.4% were 
diabetic or pre-diabetic.
In Table I, cross-sectionally, mean age decreased across quintiles of total testosterone (P-
trend=0.005). The overall age-adjusted distribution of race/ethnicity differed across quintiles 
of total testosterone (P<0.0001). After adjusting for age and race/ethnicity, mean BMI and 
mean waist circumference decreased across quintiles of total testosterone (both P-
trend<0.0001). Prevalence of current and former smoking (P<0.0001) and diabetes 
(P<0.0001) also differed across quintiles of total testosterone after adjusting for age and 
race/ethnicity.
Association between sex steroid hormone concentrations and PSA
Geometric mean serum PSA concentration by quintiles of total testosterone, free 
testosterone, 3α-diol-G, estradiol and SHBG after age and race/ethnicity adjustment and 
after further multivariable adjustment is shown in Table II. PSA concentration increased 
across quintiles of total testosterone (P-trend=0.002), free testosterone (P-trend<0.001), and 
3α-diol-G (P-trend=0.01) after age and race/ethnicity adjustment. These same patterns were 
observed after further multivariable adjustment for total testosterone (P-trend=0.02), free 
testosterone (P-trend=0.03), and 3α-diol-G (P-trend=0.002). While PSA concentration was 
not associated with SHBG after age and race/ethnicity adjustment (P-trend=0.93), it was 
inversely associated after multivariable adjustment (P-trend=0.01). Adjustment for total 
testosterone concentration explained the shift, which we determined by entering each 
covariate one at a time into the model along with age and race/ethnicity. There was no 
statistically significant pattern in PSA concentration across quintiles of estradiol. Given the 
similar patterns in PSA across quintiles of total testosterone, free testosterone, and 3α-diol-
G (Figure), we focused on the association between total testosterone and PSA for the 
remainder of the study.
Stratified analyses
Table III shows multivariable-adjusted geometric mean serum PSA concentration by 
quintiles of total testosterone stratified by categories of race/ethnicity, adiposity, and age. 
Overall, Hispanic men had the lowest total testosterone concentration and non-Hispanic 
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whites had the highest. PSA concentration increased across total testosterone quintiles in 
non-Hispanic whites (P-trend=0.02) and non-Hispanic blacks (P-trend=0.008). Although not 
statistically significant, this same pattern was observed in Hispanic men. There was no 
interaction between race/ethnicity and total testosterone (P-interaction=0.85).
Men with lower adiposity (BMI ≤28.02 kg/m2 and waist circumference <102 cm) had 
overall higher levels of PSA than men with higher adiposity; however, the same increasing 
pattern in PSA was observed across quintiles of total testosterone in both groups (P-
trend=0.004 and 0.02, respectively). There was no interaction between adiposity and total 
testosterone (P-interaction=0.65).
PSA concentration increased across quintiles of total testosterone among older men (>52 
years, P-trend=0.01), and was higher than in younger men. Although not significant, this 
same increasing pattern was also observed in younger men. There was a possible interaction 
between age and total testosterone (P-interaction=0.06).
Odds of higher serum PSA concentration
ORs of higher PSA were estimated across quintiles of total testosterone after age- and race/
ethnicity-adjustment and after further multivariable-adjustment (Table IV). Men with higher 
total testosterone levels were more likely to have a PSA >4.0, >2.5, and >2.0 ng/mL than 
those with lower total testosterone levels.
Discussion
In this nationally representative, cross-sectional sample of US men aged 40+ years old 
without a prostate cancer diagnosis, those with a higher serum total testosterone 
concentration had higher serum total PSA concentration taking into account age, race/
ethnicity, and other factors. We observed this same pattern of association between PSA and 
both free testosterone and 3α-diol-G. Serum SHBG concentration was associated with lower 
PSA concentration, but only after multivariable adjustment including for total testosterone. 
The odds of higher PSA were greater among men with higher total testosterone levels, 
including for the clinical cutpoint of 4.0 ng/mL. This suggests men in the general population 
who are of the target age for prostate cancer screening who have higher total testosterone 
levels may be at increased risk of unnecessary prostate biopsy due to an elevated PSA.
PSA is serine protease produced by prostate luminal epithelial cells [9]. While transcription 
of the PSA gene is transactivated by the androgen receptor with bound androgen, it is not 
clear whether circulating androgen influences circulating PSA. Indirect evidence for the 
influence of circulating androgens on PSA comes from the fact that men treated for prostate 
cancer with androgen deprivation therapy experience a decline in serum PSA concentration. 
This decline is probably due to both fewer cancer cells remaining to produce PSA, and 
substantially reduced testosterone available to all PSA-producing cells. Our study supports 
that even across the range of PSA in middle aged and older men without the diagnosis of 
prostate cancer, serum total testosterone concentration is positively associated with serum 
PSA concentration. This pattern was present for men across racial and ethnic groups, men 
who were leaner and heavier, and men who were younger and older.
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Other investigators have reported on the link between testosterone and PSA concentrations, 
but none used a nationally representative sample of men. A pooled analysis of prospective 
epidemiologic studies on hormones and prostate cancer found that, among controls, baseline 
PSA concentration was weakly positively correlated with free testosterone concentration 
(6,479 men, r=0.11), but not with total testosterone (7,143 men, r=0.08), other androgens, 
estradiol, free estradiol, or SHBG [10] when taking into account age; detailed analyses were 
not performed. In men with sexual dysfunction, Corona et al. [11] found that those who 
were in the lowest decile of total testosterone had a lower PSA concentration when 
compared to all other men, otherwise, no dose-response across testosterone concentration 
was observed. This same pattern was present also in the subset of these men free of prostate 
diseases. Also in men with sexual dysfunction, but restricting to PSA concentration <4 
ng/mL, Rastrelli et al. [12] found that men with total testosterone <8 nmol/L were more 
likely to have a low PSA concentration (<0.65 ng/mL) than men with higher total 
testosterone. In contrast, in men referred for prostate biopsy for an elevated PSA or 
abnormal digital rectal examination, Botelho et al. [13] reported that total testosterone 
concentration was not correlated with total PSA. While these studies taken together support 
that circulating levels of androgens and PSA are related to some extent, our study 
specifically fills the gap in understanding the link between circulating androgens and PSA in 
a general population of men not enriched for clinical states that may distort the association.
To our knowledge, this is the first nationally representative study of circulating sex steroid 
hormones and PSA in adult males without prostate cancer or acute conditions (e.g., 
symptomatic prostatitis or prostate infection) or recent procedures that affect PSA 
concentration. NHANES participants are selected using a complex stratified, multistage, 
probability-cluster design insuring that the sample is representative of the general US 
population and not just those seeking screening. We included only men who participated in 
the morning session to minimize the influence of diurnal testosterone production. We were 
able to conduct analyses that took into account potential confounders and analyses that were 
restricted to important subgroups, including three major race/ethnicity groups in US.
Some of the men had PSA concentrations in the elevated range (5.2% of the men had PSA 
>4 ng/mL). We do not know whether any of these men were later diagnosed with prostate 
cancer. Further, among the men with PSA ≤ 4 ng/mL, we do not know who may have had 
occult prostate cancer. Also, we could not assess the relative contributions of androgens 
versus asymptomatic intraprostatic inflammation [14] to serum PSA. However, not having 
excluded men with prostate cancer or asymptomatic inflammation does not affect the 
inferences from our findings because our goal was to describe the hormone-PSA link in men 
in the general population and perhaps to be able to inform prostate cancer screening 
algorithms.
The measurement of total testosterone concentration was done with good precision and 
sensitivity by competitive electrochemiluminescence immunoassay. We did not use the 
more sensitive, but more expensive methods of gas or liquid chromatography coupled with 
mass spectrometry. The calculation of free testosterone was done using published formulae 
that provide well-documented correlation with the values of directly measured assays [15]; 
some noise in its estimation may have occurred due to the imperfect specificity of the 
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measurement of albumin by the Bromcresol Purple method [16]. However, we were still 
able to detect a positive association. While the precision in the measurement of estradiol 
concentration was somewhat lower than for the other hormones, we did not find differences 
in PSA concentrations even when comparing the highest and lowest quintiles of estradiol, 
suggesting no major influence on PSA. We measured hormones and PSA only once for each 
man, and as such the concentrations may not represent the men's usual levels over time. 
Finally, this study was cross-sectional, thus we could not determine the relationship between 
changing testosterone concentration (e.g., with aging or weight gain) and changing PSA 
concentration.
Conclusions
In summary, in this nationally representative sample of middle-aged and older men, those 
with higher total testosterone and 3α-diol-G in circulation had higher PSA in circulation, 
even after taking into account age and other factors. At this time we are not suggesting that 
men should have their serum testosterone concentration measured. However, we envision 
that knowledge of the size of this association may be used in the future to enhance tools for 
clinical decision-making following an elevated screening PSA.
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Figure. 
Geometric mean* serum total PSA concentration by circulating androgen concentrations, 
378 men, 40-85 years old, NHANES 2001-2004.
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Table II
Adjusted geometric mean serum total PSA concentration by quintile of serum sex steroid hormone 
concentrations, 378 men, 40-85 years old, NHANES 2001-2004
Quintiles of sex steroid hormone concentrations N Geometric mean serum total PSA concentration in ng/mL (95% CI)
Age and race/ethnicity adjusted* Multivariable adjusted†
Total testosterone (ng/mL)
    < 3.16 89 0.80 (0.67, 0.95) 0.79 (0.65, 0.96)
    3.16 - < 4.04 75 0.82 (0.68, 0.98) 0.79 (0.67, 0.94)
    4.04 - < 4.88 61 1.11 (0.94, 1.31) 1.12 (0.96, 1.31)
    4.88 - < 6.02 75 1.09 (0.86, 1.39) 1.11 (0.87, 1.43)
    ≥ 6.02 78 1.14 (1.00, 1.30) 1.16 (0.91, 1.48)
P-trend‡ 0.002 0.02
Free testosterone (ng/mL)
    < 0.0586 96 0.68 (0.56, 0.82) 0.72 (0.57, 0.90)
    0. 0586- < 0.0757 87 0.88 (0.72, 1.08) 0.89 (0.73, 1.09)
    0. 0757- < 0.0921 68 1.10 (0.91, 1.33) 1.10 (0.91, 1.32)
    0.0921 - < 0.1117 66 1.16 (0.93, 1.45) 1.13 (0.90, 1.42)
    ≥ 0.1117 61 1.19 (1.00, 1.40) 1.15 (0.93, 1.43)
P-trend‡ < 0.001 0.03
Androstanediol glucuronide (ng/mL)
    < 4.79 88 0.72 (0.60, 0.86) 0.73 (0.60, 0.87)
    4.79 - < 5.99 76 1.03 (0.87, 1.22) 1.00 (0.84, 1.20)
    5.99 - < 7.79 84 1.02 (0.83, 1.24) 1.00 (0.79, 1.26)
    7.79 - < 10.21 63 1.05 (0.85, 1.31) 1.06 (0.86, 1.30)
    ≥ 10.21 67 1.14 (0.96, 1.36) 1.18 (1.02, 1.37)
P-trend‡ 0.01 0.002
Total estradiol (pg/mL)
    < 20.60 94 0.93 (0.74, 1.17) 1.00 (0.81, 1.23)
    20.60 - < 27.43 70 0.85 (0.73, 0.99) 0.93 (0.79, 1.10)
    27.43 - < 33.48 69 1.15 (0.96, 1.39) 1.22 (1.00, 1.49)
    33.48 - < 43.64 83 0.89 (0.73, 1.07) 0.84 (0.71, 1.00)
    ≥ 43.64 62 1.11 (0.95, 1.30) 0.95 (0.76, 1.17)
P-trend‡ 0.20 0.64
Sex hormone binding globulin (nmol/L)
    < 24.14 59 1.01 (0.79, 1.29) 1.32 (1.01, 1.71)
    24.14 - < 32.96 74 0.99 (0.84, 1.17) 1.07 (0.91, 1.26)
    32.96 - < 41.03 66 1.12 (0.93, 1.36) 1.10 (0.92, 1.32)
    41.03 - < 51.95 73 0.78 (0.65, 0.93) 0.71 (0.60, 0.83)
    ≥ 51.95 106 1.04 (0.81, 1.35) 0.82 (0.66, 1.02)
P-trend‡ 0.93 0.01
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*Adjusted for age in years (spline) and race/ethnicity (NH White, NH Black, Hispanic, Other).
†Adjusted for age in years (spline), race/ethnicity (NH White, NH Black, Hispanic, Other), body mass index (categorical), waist circumference 
(continuous), cigarette smoking status (non-smoker, former smoker, current smoker), type II diabetes (non-diabetic, pre-diabetic, diabetic), and 
mutually for the other hormones (total testosterone: estradiol and sex hormone binding globulin (SHBG), free testosterone: estradiol, 
androstanediol glucuronide: estradiol and SHBG, estradiol: total testosterone and SHBG, SHBG: total testosterone and estradiol; continuous, 
natural logarithm-transformed).
‡
P-trend calculated modeling natural logarithm-transformed PSA concentration and median hormone concentration by quintile.
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Table IV
Odds ratio (OR) of higher serum total PSA concentration by quintile of serum total testosterone concentration, 
378 men, 40-85 years old, NHANES 2001-2004
Quintile of serum total testosterone concentration (ng/mL) N OR of higher serum total PSA concentration (95% CI)
Age and race/ethnicity adjusted* Multivariable adjusted†
PSA concentration > 4.0 ng/mL (5.2%)
< 3.16 89 1.00 (reference) 1.00 (reference)
3.16 - < 4.04 75 2.14 (0.45, 10.14) 1.98 (0.34, 11.71)
4.04 - < 4.88 61 5.85 (0.71, 47.96) 5.43 (0.42, 70.95)
4.88 - < 6.02 75 5.88 (1.32, 26.21) 6.61 (1.22, 35.65)
≥ 6.02 78 7.04 (1.23, 40.36) 5.54 (0.49, 62.90)
Per quintile increase 1.57 (1.07, 2.31) 1.56 (0.95, 2.56)
P-trend‡ 0.02 0.10
PSA concentration ≥ 2.5 ng/mL (11.3%)
< 3.16 89 1.00 (reference) 1.00 (reference)
3.16 - < 4.04 75 1.63 (0.47, 5.60) 1.71 (0.46, 6.40)
4.04 - < 4.88 61 2.66 (0.62, 11.54) 3.41 (0.55, 21.08)
4.88 - < 6.02 75 3.08 (0.98, 9.67) 4.88 (1.17, 20.32)
≥ 6.02 78 6.33 (2.23, 17.99) 11.14 (1.84, 67.29)
Per quintile increase 1.54 (1.18, 2.01) 1.78 (1.16, 2.73)
P-trend‡ 0.001 0.006
PSA concentration ≥ 2.0 ng/mL (15.8%)
< 3.16 89 1.00 (reference) 1.00 (reference)
3.16 - < 4.04 75 1.17 (0.26, 5.30) 1.10 (0.23, 5.16)
4.04 - < 4.88 61 3.58 (0.64, 20.17) 3.79 (0.61, 23.60)
4.88 - < 6.02 75 2.08 (0.33, 13.06) 2.66 (0.45, 15.81)
≥ 6.02 78 3.62 (0.73, 17.86) 4.48 (0.74, 27.16)
Per quintile increase 1.35 (0.95, 1.91) 1.44 (0.97, 2.12)
P-trend‡ 0.08 0.08
*Adjusted for age in years (spline) and race/ethnicity (NH White, NH Black, Hispanic, Other).
†Adjusted for age in years (spline), race/ethnicity (NH White, NH Black, Hispanic, Other), body mass index (categorical), waist circumference 
(continuous), cigarette smoking status (non-smoker, former smoker, current smoker), type II diabetes (non-diabetic, pre-diabetic, diabetic), 
estradiol (continuous, natural logarithm-transformed), sex hormone binding globulin (continuous, natural logarithm-transformed).
‡
P-trend calculated modeling the natural logarithm-transformed PSA concentration and median total testosterone concentration by quintile.
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